Genmab – more things cooking?

Genmab CEO, Jan van de Winkel, held a presentation on wednesday the 16th september in New York. Genmab has had a very busy year with advances in the clinical development for Daratumumab, Arzerra and Humax TF. They have made a number of deals, including one with insulin powerhouse Novo Nordisk. And as Jan van de…

Vores uafhængige analyser er tilgængelig mod betaling / This content is for Peter Hildebrandt Fundmanager Subscription and Premium – ALL fundmanagers members only.
Log In Register